These data suggest that FLT3+ patients manifest more aggressive CML pathologies and show worse overall survival compared to FLT3− BP patients (Fig. 4F and G, S4D, Table S2). Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.